A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin

S. Goswami, S. W. Yee, F. Xu, S. B. Sridhar, J. D. Mosley, A. Takahashi, Michiaki Kubo, S. Maeda, R. L. Davis, D. M. Roden, M. M. Hedderson, K. M. Giacomini, R. M. Savic

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

One-third of type-2 diabetic patients respond poorly to metformin. Despite extensive research, the impact of genetic and nongenetic factors on long-term outcome is unknown. In this study we combine nonlinear mixed effect modeling with computational genetic methodologies to identify predictors of long-term response. In all, 1,056 patients contributed their genetic, demographic, and long-term HbA1c data. The top nine variants (of 12,000 variants in 267 candidate genes) accounted for approximately one-third of the variability in the disease progression parameter. Average serum creatinine level, age, and weight were determinants of symptomatic response; however, explaining negligible variability. Two single nucleotide polymorphisms (SNPs) in CSMD1 gene (rs2617102, rs2954625) and one SNP in a pharmacologically relevant SLC22A2 gene (rs316009) influenced disease progression, with minor alleles leading to less and more favorable outcomes, respectively. Overall, our study highlights the influence of genetic factors on long-term HbA1c response and provides a computational model, which when validated, may be used to individualize treatment.

Original languageEnglish
Pages (from-to)537-547
Number of pages11
JournalClinical Pharmacology and Therapeutics
DOIs
Publication statusPublished - 01-11-2016

Fingerprint

Metformin
Disease Progression
Single Nucleotide Polymorphism
Genes
Creatinine
Alleles
Demography
Weights and Measures
Serum
Research
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Goswami, S., Yee, S. W., Xu, F., Sridhar, S. B., Mosley, J. D., Takahashi, A., ... Savic, R. M. (2016). A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. Clinical Pharmacology and Therapeutics, 537-547. https://doi.org/10.1002/cpt.428
Goswami, S. ; Yee, S. W. ; Xu, F. ; Sridhar, S. B. ; Mosley, J. D. ; Takahashi, A. ; Kubo, Michiaki ; Maeda, S. ; Davis, R. L. ; Roden, D. M. ; Hedderson, M. M. ; Giacomini, K. M. ; Savic, R. M. / A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. In: Clinical Pharmacology and Therapeutics. 2016 ; pp. 537-547.
@article{62e073550ec843f38fb57d932b58cf38,
title = "A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin",
abstract = "One-third of type-2 diabetic patients respond poorly to metformin. Despite extensive research, the impact of genetic and nongenetic factors on long-term outcome is unknown. In this study we combine nonlinear mixed effect modeling with computational genetic methodologies to identify predictors of long-term response. In all, 1,056 patients contributed their genetic, demographic, and long-term HbA1c data. The top nine variants (of 12,000 variants in 267 candidate genes) accounted for approximately one-third of the variability in the disease progression parameter. Average serum creatinine level, age, and weight were determinants of symptomatic response; however, explaining negligible variability. Two single nucleotide polymorphisms (SNPs) in CSMD1 gene (rs2617102, rs2954625) and one SNP in a pharmacologically relevant SLC22A2 gene (rs316009) influenced disease progression, with minor alleles leading to less and more favorable outcomes, respectively. Overall, our study highlights the influence of genetic factors on long-term HbA1c response and provides a computational model, which when validated, may be used to individualize treatment.",
author = "S. Goswami and Yee, {S. W.} and F. Xu and Sridhar, {S. B.} and Mosley, {J. D.} and A. Takahashi and Michiaki Kubo and S. Maeda and Davis, {R. L.} and Roden, {D. M.} and Hedderson, {M. M.} and Giacomini, {K. M.} and Savic, {R. M.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/cpt.428",
language = "English",
pages = "537--547",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

Goswami, S, Yee, SW, Xu, F, Sridhar, SB, Mosley, JD, Takahashi, A, Kubo, M, Maeda, S, Davis, RL, Roden, DM, Hedderson, MM, Giacomini, KM & Savic, RM 2016, 'A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin', Clinical Pharmacology and Therapeutics, pp. 537-547. https://doi.org/10.1002/cpt.428

A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. / Goswami, S.; Yee, S. W.; Xu, F.; Sridhar, S. B.; Mosley, J. D.; Takahashi, A.; Kubo, Michiaki; Maeda, S.; Davis, R. L.; Roden, D. M.; Hedderson, M. M.; Giacomini, K. M.; Savic, R. M.

In: Clinical Pharmacology and Therapeutics, 01.11.2016, p. 537-547.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin

AU - Goswami, S.

AU - Yee, S. W.

AU - Xu, F.

AU - Sridhar, S. B.

AU - Mosley, J. D.

AU - Takahashi, A.

AU - Kubo, Michiaki

AU - Maeda, S.

AU - Davis, R. L.

AU - Roden, D. M.

AU - Hedderson, M. M.

AU - Giacomini, K. M.

AU - Savic, R. M.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - One-third of type-2 diabetic patients respond poorly to metformin. Despite extensive research, the impact of genetic and nongenetic factors on long-term outcome is unknown. In this study we combine nonlinear mixed effect modeling with computational genetic methodologies to identify predictors of long-term response. In all, 1,056 patients contributed their genetic, demographic, and long-term HbA1c data. The top nine variants (of 12,000 variants in 267 candidate genes) accounted for approximately one-third of the variability in the disease progression parameter. Average serum creatinine level, age, and weight were determinants of symptomatic response; however, explaining negligible variability. Two single nucleotide polymorphisms (SNPs) in CSMD1 gene (rs2617102, rs2954625) and one SNP in a pharmacologically relevant SLC22A2 gene (rs316009) influenced disease progression, with minor alleles leading to less and more favorable outcomes, respectively. Overall, our study highlights the influence of genetic factors on long-term HbA1c response and provides a computational model, which when validated, may be used to individualize treatment.

AB - One-third of type-2 diabetic patients respond poorly to metformin. Despite extensive research, the impact of genetic and nongenetic factors on long-term outcome is unknown. In this study we combine nonlinear mixed effect modeling with computational genetic methodologies to identify predictors of long-term response. In all, 1,056 patients contributed their genetic, demographic, and long-term HbA1c data. The top nine variants (of 12,000 variants in 267 candidate genes) accounted for approximately one-third of the variability in the disease progression parameter. Average serum creatinine level, age, and weight were determinants of symptomatic response; however, explaining negligible variability. Two single nucleotide polymorphisms (SNPs) in CSMD1 gene (rs2617102, rs2954625) and one SNP in a pharmacologically relevant SLC22A2 gene (rs316009) influenced disease progression, with minor alleles leading to less and more favorable outcomes, respectively. Overall, our study highlights the influence of genetic factors on long-term HbA1c response and provides a computational model, which when validated, may be used to individualize treatment.

UR - http://www.scopus.com/inward/record.url?scp=84990248628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990248628&partnerID=8YFLogxK

U2 - 10.1002/cpt.428

DO - 10.1002/cpt.428

M3 - Article

SP - 537

EP - 547

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -